Revised Code of Washington

Wash. Rev. Code § 69.50.212 (2026)

Schedule V

✓ current as of May 2026
Find cases: SyfertCases citing this section WA-LEGapp.leg.wa.gov JustiaTitle on Justia CornellLII Search CasesGoogle Scholar
Unless specifically excepted by state or federal law or regulation or more specifically included in another schedule, the following controlled substances are listed in Schedule V:
(a) [(1)] Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth in this subsection, which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than those possessed by the narcotic drug alone:
(1) [(a)] Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
(2) [(b)] Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
(3) [(c)] Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
(4) [(d)] Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
(5) [(e)] Not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
(6) [(f)] Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
(b) [(2)] Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: Pyrovalerone.
(c) [(3)] Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:
(1) [(a)] Lacosamid, [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];
(2) [(b)] Pregabalin{(S)-3-(aminomethyl)-5-methylhexanoic acid}.
The controlled substances listed in this section may be added, rescheduled, or deleted as provided for in RCW 69.50.201.
[ 2010 c 177 s 6; 1993 c 187 s 12; 1986 c 124 s 7; 1980 c 138 s 5; 1971 ex.s. c 308 s 69.50.212.]

Notes:

Pharmacy quality assurance commission may change schedules of controlled substances: RCW 69.50.201.
Notes of Decisions
Cited in 2 cases, 2013–2013 · leading case: State v. Zillyette, 307 P.3d 712 (Wash. 2013).
State v. Zillyette, 307 P.3d 712 (Wash. 2013). “…Wiggins, González, and Gordon McCloud, JJ., concur. RCW 69.50.204. RCW 69.50.206. RCW 69.50.208. RCW 69.50.210. RCW 69.50.212.”
State v. Zillyette (Wash. 2013). “5 RCW 69.50.212. 6 State v. Zillyette, No. 87614-2 satisfy the essential element rule because it is over inclusive.”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.